Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized placebo-controlled double-blind phase 3 study of Colibiogen Oral in irritable bowel syndrome
2011-001743-78Phase 3Completed
- Sponsor
- Laves-Arzneimittel GmbH
- Start
- May 2011
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Colibiogen in irritable bowel syndrome (IBS) (3 arms), sponsored by Laves-Arzneimittel GmbH. Primary endpoint: Responder rate for global improvement of irritable bowel syndrome. Started May 2011; status: completed.
02
Drugs
Colibiogen
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2011-001743-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001743-78.